CRB 4001
Alternative Names: CRB-4001; JD-5037Latest Information Update: 28 Dec 2022
Price :
$50 *
At a glance
- Originator Jenrin Discovery
- Developer Corbus Pharmaceuticals; National Institutes of Health (USA)
- Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Pyrazoles; Small molecules; Sulfonamides
- Mechanism of Action Cannabinoid 1 receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic nephropathies; Insulin resistance; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Diabetic-nephropathies in USA (PO)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Insulin-resistance in USA (PO)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)